Hospitals preparing calendar-year 2027 budgets for fall board approval must separate final payment parameters from uncertain enrollment, utilization, and contracting assumptions. FY2027 IPPS is effective; CY2027 outpatient proposals and AEP-related coverage movement require explicitly labeled sensitivities. The task is to show the board which inputs are final, which remain forecasts, and when each assumption will be refreshed.
October is when many hospitals finalize the revenue assumptions that go into the 2027 operating budget for board approval. The enrollment period that sets 2027 Medicare payer mix does not close until 12-07-2026. The CY2027 outpatient payment proposals are not final. Some MA contracts are in active negotiation. This year's budget cycle requires the board presentation to be explicit about which inputs are settled and which are forecasts.
The discipline is not about managing uncertainty: it is about not presenting forecast assumptions as confirmed figures when the underlying data has not resolved.
The FY2027 Hospital Inpatient Prospective Payment System final rule took effect 10-01-2026. The operating rate update for hospitals that meet quality reporting requirements is confirmed at 2.3%, reflecting a 3.2% market basket update reduced by a 0.9% productivity adjustment.
The 2.3% applies to the base operating rate, not to the full payment per case. Each hospital's actual case payment reflects DRG weights, case mix, wage-index value and applicable reclassification status, teaching hospital adjustments (IME and direct GME are separate payment streams with their own methodologies), DSH and uncompensated care using the applicable FY2027 methodology and CMS's finalized hospital-specific parameters, and outlier thresholds. Build the inpatient revenue projection from the hospital's specific final FY2027 parameters, not from the headline rate alone.
For 340B hospitals, the CY2027 OPPS rule on outpatient drug payment is not final. CMS is collecting drug acquisition cost data through a survey mechanism intended to inform that rule. Until the CY2027 OPPS final rule is published, 340B outpatient drug revenue should be carried as a labeled sensitivity rather than a point estimate. Note that the 340B uncertainty does not depend on the AEP closing date. The OPPS final rule has its own timeline, and the assumption can be refreshed when that rule publishes, not only in December.
Annual Enrollment Period runs 10-15-2026 through 12-07-2026. Enrollment transitions take effect 01-01-2027. The 2027 Medicare payer mix at your hospital is not observable until after December 7.
For budgeting, anchor the Medicare payer mix to recent local and hospital encounter data adjusted for announced changes, not to a national penetration average or a prior-year flat assumption. The variables that inform the sensitivity range include:
Announced plan changes. The 2027 MA landscape files, reflecting service area approvals and changes, are available from CMS. A county-level exit creates a population that may select another MA plan, return to Original Medicare with standard supplemental coverage options, or transition under an applicable CMS-approved arrangement. A disappearing plan does not establish where its former members will land. For local exit verification, compare the relevant CMS plan and service-area files and carrier notices. A state-level plan count or a single year's landscape file alone is not sufficient to estimate member displacement in your service area.
Star Ratings effect. The 2027 Star Ratings, released 10-08-2026, confirmed that 63% of MA-PD contracts are below the 4.0-star quality bonus threshold. Plans at 3.5 stars face 2028 benefit design decisions under constrained bonus payment economics. Some plans will reduce supplemental benefits, reprice premiums, or change market footprint for 2028. That affects 2028 planning; for 2027, the actionable question is which plans in your specific service area have announced changes, not what the national distribution implies about aggregate enrollment movement.
Enrollment-period dynamics. Beneficiaries can and do switch during AEP based on premium, benefit, and network changes. The beneficiary population in your service area and its MA plan preferences are the relevant inputs, not a national average penetration rate.
For MA contracts not subject to renewal in this cycle, use the executed contract terms, including applicable rate escalators, Medicare-linked provisions, carve-outs, and other adjustments. These terms are known. The payment rate is not simply the current rate applied flat.
For contracts in active renegotiation, carry two scenarios labeled by outcome range approved by management. Avoid presenting a single assumed rate as settled before the negotiation closes.
For the contracting-leverage argument: hospitals can present documented outcomes, access, care-transition performance, and total-cost evidence relevant to the payer's population. Whether those results translate into better rates depends on the negotiation, the payer's network alternatives, your market position, and the specific contract terms under discussion. Do not treat quality outcomes as a reliable predictor of negotiated rates in the absence of evidence from your specific negotiation context. Upcoming third-quarter earnings releases will provide updated context on carrier medical-cost trends and margin recovery.
The board presentation should organize the 2027 revenue build into three categories:
Final regulatory and executed-contract parameters. IPPS operating rate, applicable hospital-specific adjustments, wage index, teaching payments, DSH and uncompensated care using finalized CMS parameters, and executed MA contract terms for non-renewing agreements. These inputs are confirmed. Present them with sources.
Management-approved forecasts. Volume, case mix, payer mix based on recent local data adjusted for known changes, and MA contract terms for agreements in negotiation, labeled with the range and the renewal timeline. These are forecasts, not confirmed inputs. Present them with the methodology and update triggers.
Explicitly labeled sensitivities. CY2027 340B outpatient drug payment using the current proposed policy as the reference case, with alternative scenarios if relevant. AEP enrollment shift scenarios based on announced plan changes in the service area. MA contracting outcomes for agreements in renegotiation, bounded by a management-approved range. These are unresolved. Present them with the resolution dates: the OPPS final rule, December 7, and contract execution.
The board that sees which inputs are confirmed, which are forecasts, and when each uncertainty resolves is better equipped to evaluate the budget's assumptions than a board presented with a single revenue number that embeds unresolved variables as if they were settled.
Sources: CMS FY2027 IPPS final rule, effective 10-01-2026 (cms.gov); CMS 2027 MA landscape files (released late September 2026); CMS 2027 Star Ratings fact sheet, 10-08-2026 (cms.gov).
Discover how Addie helps health systems, post-acute providers, and payers improve throughput, reduce avoidable days, and deliver better transitions of care.
Get Started